Structure Therapeutics (GPCR) Income from Continuing Operations (2022 - 2026)
Structure Therapeutics' (GPCR) quarterly Income from Continuing Operations came in at 75968000.0 in Q1 2026, down 62.21% year-on-year from 201028892.76 in Q1 2025, and down 142.73% quarter-over-quarter from 177783000.0 in Q4 2025.
Structure Therapeutics (GPCR) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Structure Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 75968000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 62.21% year-over-year to 75968000.0 in Q1 2026; TTM through Mar 2026 was 25558000.0, a 15.47% increase from a year earlier, with the FY2025 full-year figure at 3577000.0, up 137.9% from the prior year.
- Income from Continuing Operations fell to 75968000.0 in Q1 2026 per GPCR's latest filing, from 177783000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 177783000.0 in Q4 2025 and bottomed at 75968000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 23280000.0 (2023), against an average of 5786588.24.
- Biggest YoY gain for Income from Continuing Operations was 132.06% in 2025; the steepest drop was 136.85% in 2025.
- Year by year, Income from Continuing Operations stood at 32323000.0 in 2022, then jumped by 72.31% to 55696000.0 in 2023, then jumped by 37.55% to 76610000.0 in 2024, then jumped by 132.06% to 177783000.0 in 2025, then sank by 142.73% to 75968000.0 in 2026.
- Per Business Quant, the three latest GPCR Income from Continuing Operations figures stand at 75968000.0 (Q1 2026), 177783000.0 (Q4 2025), and 65712000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Structure Therapeutics | 10.71 Bn | 10.71 Bn | - | -75.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75.97 Mn |
| Dec 31, 2025 | 177.78 Mn |
| Sep 30, 2025 | -65.71 Mn |
| Jun 30, 2025 | -61.66 Mn |
| Mar 31, 2025 | -46.83 Mn |
| Dec 31, 2024 | 76.61 Mn |
| Sep 30, 2024 | -33.98 Mn |
| Jun 30, 2024 | -26.03 Mn |
| Mar 31, 2024 | -26.04 Mn |
| Dec 31, 2023 | 55.70 Mn |
| Sep 30, 2023 | -23.86 Mn |
| Jun 30, 2023 | -23.28 Mn |
| Mar 31, 2023 | -17.98 Mn |
| Dec 31, 2022 | 32.32 Mn |
| Sep 30, 2022 | -12.42 Mn |
| Jun 30, 2022 | -13.95 Mn |
| Mar 31, 2022 | -13.08 Mn |